Equity Profile

SMMT

Summit Therapeutics Inc.

Health CareBiotechnology$11.2B

Aug10Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Summit Therapeutics Inc. is a biotechnology company focused on developing innovative medicines for serious diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a critical measure of profitability that investors closely monitor to gauge the company's financial health.

N/A

Revenue Growth

Revenue growth indicates the company's ability to expand its market presence and attract customers, which is vital for future success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SMMT Q2-2026 Earnings Preview

Context

Company Snapshot

Summit Therapeutics Inc. is a biotechnology company focused on developing innovative medicines for serious diseases. Operating in the health care sector, it aims to address unmet medical needs through its unique therapeutic approaches.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+19.76%

Avg Stock Reaction

-4.23%

Last Quarter Recap

In Q1-2026, Summit Therapeutics reported an EPS of -$0.15, outperforming expectations by nearly 55%. The stock saw a positive reaction, gaining over 3% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are anticipating a strong performance from Summit Therapeutics, especially given its history of beating EPS estimates. However, uncertainty remains due to the lack of specific guidance.

Bull Case

If the company continues its trend of beating EPS estimates and provides positive updates on clinical trials, it could see significant stock appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing updates on drug development, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of ongoing clinical trials?

Updates on clinical trials can greatly influence investor confidence and stock performance, making this a key focus for the market.

Will there be any guidance on future revenue expectations?

Clear guidance on revenue can help investors assess the company's growth trajectory and financial stability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of positive clinical trial results, which could significantly boost investor sentiment and stock price.

Supporting Evidence

Summit has consistently beaten EPS estimates, suggesting a stronger operational performance than anticipated.

The options market is pricing a large move, indicating that many investors expect significant news, which could be overlooked by the consensus.

Historical patterns show that the stock often reacts positively to clinical trial updates, which may not be fully factored into current expectations.

Key Risk

If clinical trial results exceed expectations, it could lead to a substantial upward revision in stock price.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for continued growth against the risks of unmet expectations and the company's ability to advance its drug pipeline.

Bull Confirmed If

A positive update on clinical trial outcomes or a significant reduction in EPS loss could confirm the bull case.

Bear Confirmed If

Failure to provide any updates on clinical trials or a worse-than-expected EPS could confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±50.31%

Historical Avg

±5.8%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty or anticipation surrounding the earnings report.

Options are pricing ±50.3% while SMMT has averaged ±5.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

109.2%

Calls (422K)P/C Ratio: 0.88Puts (205K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Summit beats expectations, history suggests the stock could rise by around 5.8%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see a muted response, reflecting cautious investor sentiment.

Miss

A miss could lead to a decline of about 1.4%, as seen in previous quarters, indicating disappointment among investors.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status and results of ongoing clinical trials.
2Any guidance on future revenue expectations and growth strategies.
3Management's commentary on competitive positioning in the biotechnology sector.
4Insights into partnerships or collaborations that may enhance product development.
5Details on any upcoming product launches or regulatory submissions.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Tempus AI, Inc.

Company Snapshot

Summit Therapeutics Inc. is a biotechnology company focused on developing innovative medicines for serious diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a critical measure of profitability that investors closely monitor to gauge the company's financial health.

N/A

Revenue Growth

Revenue growth indicates the company's ability to expand its market presence and attract customers, which is vital for future success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SMMT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+19.76%

Avg Stock Reaction

-4.23%

Last Quarter Recap

In Q1-2026, Summit Therapeutics reported an EPS of -$0.15, outperforming expectations by nearly 55%. The stock saw a positive reaction, gaining over 3% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are anticipating a strong performance from Summit Therapeutics, especially given its history of beating EPS estimates. However, uncertainty remains due to the lack of specific guidance.

Bull Case

If the company continues its trend of beating EPS estimates and provides positive updates on clinical trials, it could see significant stock appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing updates on drug development, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of ongoing clinical trials?

Updates on clinical trials can greatly influence investor confidence and stock performance, making this a key focus for the market.

Will there be any guidance on future revenue expectations?

Clear guidance on revenue can help investors assess the company's growth trajectory and financial stability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of positive clinical trial results, which could significantly boost investor sentiment and stock price.

Supporting Evidence

Summit has consistently beaten EPS estimates, suggesting a stronger operational performance than anticipated.

The options market is pricing a large move, indicating that many investors expect significant news, which could be overlooked by the consensus.

Historical patterns show that the stock often reacts positively to clinical trial updates, which may not be fully factored into current expectations.

Key Risk

If clinical trial results exceed expectations, it could lead to a substantial upward revision in stock price.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for continued growth against the risks of unmet expectations and the company's ability to advance its drug pipeline.

Bull Confirmed If

A positive update on clinical trial outcomes or a significant reduction in EPS loss could confirm the bull case.

Bear Confirmed If

Failure to provide any updates on clinical trials or a worse-than-expected EPS could confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±50.31%

Historical Avg

±5.8%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty or anticipation surrounding the earnings report.

Options are pricing ±50.3% while SMMT has averaged ±5.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

109.2%

Calls (422K)P/C Ratio: 0.88Puts (205K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Summit beats expectations, history suggests the stock could rise by around 5.8%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see a muted response, reflecting cautious investor sentiment.

Miss

A miss could lead to a decline of about 1.4%, as seen in previous quarters, indicating disappointment among investors.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status and results of ongoing clinical trials.
2Any guidance on future revenue expectations and growth strategies.
3Management's commentary on competitive positioning in the biotechnology sector.
4Insights into partnerships or collaborations that may enhance product development.
5Details on any upcoming product launches or regulatory submissions.